Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 1/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.42 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.42 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | CD38 | P28907 | 2/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP8 | P22894 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.31 |
| ▸ | TAS1R2 | Q8TE23 | 3/20 | 0.31 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18987649 | 1.00 | PDK1 (0.42) | PDK1PDK2PDK3PDK4PKM | |
| SCHEMBL1700015 | 0.80 | EPHX1 (0.40) | PDK1PDK2PDK3PDK4PKM | |
| SCHEMBL28938310 | 0.80 | BTK (0.48) | PDK1PDK2PDK3PDK4EPHX1 | |
| SCHEMBL17335965 | 0.77 | EPHX1 (0.46) | PDK1PDK2PDK3PDK4PKM | |
| SCHEMBL17335967 | 0.77 | EPHX1 (0.46) | PDK1PDK2PDK3PDK4PKM | |
| SCHEMBL6658887 | 0.74 | EPHX2 (0.50) | PKMEPHX1POLBEPHX2MMP2 | |
| SCHEMBL245467 | 0.74 | — | — | |
| SCHEMBL30687981 | 0.73 | CD38 (0.39) | PDK1PDK2PDK3PDK4PKM | |
| SCHEMBL28722478 | 0.73 | ATM (0.41) | PDK1PDK2PDK3PDK4CD38 | |
| SCHEMBL23573423 | 0.72 | EPHX1 (0.63) | PDK1PDK2PDK3PDK4PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3390384-B1 | QUINOLINE-3-CARBOXAMIDES AS H-PGDS INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2021-09-15 | — | — | EP | disclosed |
| US-20210238162-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-08-05 | — | — | US | disclosed |
| EP-3390384-A1 | QUINOLINE-3-CARBOXAMIDES AS H-PGDS INHIBITORS | Astex Therapeutics Limited (GB) | 2018-10-24 | — | — | EP | disclosed |
| WO-2017103851-A1 | QUINOLINE-3-CARBOXAMIDES AS H-PGDS INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2017-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238162-A1 | CHEMICAL COMPOUNDS | HPGDS, PTGS1, PTGIS | PDK1 312/4885PDK2 423/4885PDK3 397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.